Review Article

Helicobacter Pylori Infection Induces Intestinal Dysbiosis That Could Be Related to the Onset of Atherosclerosis

Avilés-Jiménez Francisco

Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, UMAE Pediatria. Centro Médico Nacional Siglo XXI. IMSS, Ciudad de México, Mexico

Correspondence should be addressed to Avilés-Jiménez Francisco; fcoavilesj@hotmail.com

Received 28 March 2022; Revised 5 October 2022; Accepted 6 October 2022; Published 22 October 2022

1. Introduction

Cardiovascular diseases (CVDs) are a group of heart and blood vessels disorders, responsible for disability and premature mortality that include ischemic heart disease (IHD), coronary artery disease, cerebrovascular events (strokes), high blood pressure, and blockage of different vessels of the circulatory system, and they represent one of the first causes of death globally. According to the World Health Organization, 17.9 million people die every year due to CVDs, and around 75% of all deaths occur in low-income countries. Although these problems occur mainly in the elderly, there is some incidence in younger people [1]. The recognized risk factors for CVDs are hypertension, diabetes, hyperlipidemia, obesity, smoking, physical inactivity, and stress conditions as well as some genetic factors associated to an increased risk of CVDs [2–7]. However, not all cases present these factors and an undetermined portion of individuals develop symptoms early in life [8]. Under this scenario, it is relevant to study the role and possible interactions between these and new factors like the microbiota and bacterial infections to gain knowledge of the mechanisms that govern the establishment of CVDs.

1.1. The Initial Step in the CVDs Is the Development of Atherosclerosis. Atherosclerosis is a chronic inflammatory process characterized by lipid, fibrous tissue, and cellular components accumulation on the arterial cell wall, forming a plaque called atheroma that disorganizes the architecture, alters the vascular function, and reduces the heart blood flow. Several components of the inflammatory response including peripheral blood mononuclear cells and macrophages participate in the initial damage. They respond to an increased expression of cellular adhesion molecules like
\(\beta_2\) and \(\beta_1\)-integrins, the E-selectin and P-selectin ligands, together with an increased endothelial permeability. Macrophages transform into foam cells by capture of modified low-density lipoproteins (LDL) and smooth muscle cells migrate towards the atheroma. These processes reduce the blood vessel lumen causing ischemia, and if a subsequent erosion or plaque rupture happens, a thrombotic event might result with fatal consequences. There are two possible initiators of an atheroma, a lesion in the vascular system due to a chemical compound or the immune response against an infectious agent [9]. In the initial steps of \(H.\) pylori infection, there are subclinical inflammation and metabolic disorders, and the same conditions are also observed in atherosclerosis. These similarities rise the question, is \(H.\) pylori infection associated with atherosclerosis through a common link or process? One hypothesis for this problem is that the common link is changes in the intestinal microbiota, which have been widely related to both pathologies.

2. Microbiota and Atherosclerosis

The term “microbiota” includes all the microorganisms (prokaryotes, archaea, protozoa, fungi, and viruses) that populate the human body, while the term “microbiome” refers to a characteristic microbial community occupying a reasonable well-defined habitat and their corresponding set of genes and genomes as well as the products of the microbiota and the host environment [10–13]. The human microbiota performs functions which are essential for health maintenance, involving the immune system activity and energy homeostasis. The microbial composition is a signature for each body habitat; however, the diversity and abundance vary within and among individuals. The gut microbiota is home to the largest number of species, and consequently, the number of metabolic processes is greater compared to other regions of the body. The phyla Firmicutes and Bacteroidetes account for >98% of all species, and the rest is distributed among Actinobacteria, Fusobacteria, Proteobacteria, Verrucomicrobia, and Cyanobacteria, whose proportions remain relatively stable in time [14]. When these proportions are altered, a state of dysbiosis is produced which is characterized by diversity loss, changes in the type and quantity of organisms and the metabolic processes [15]. In this review, the term microbiota will be used to refer to the intestinal microbiota, which is the main interest of this work.

2.1. Dysbiosis Is Associated with Atherosclerosis and CVDs

In recent years, the role of microbiota in relation to CVDs has been the object of extensive analysis (Table 1). Some hypotheses have been formulated to explain the nature of these associations. One of them propose that lipopolysaccharide (LPS) from Gram-negative bacteria induces a low-grade systemic inflammation, promoting CVD by activation of Toll-like receptor 4, and the expression of proinflammatory mediators such as IFN\(\gamma\), IL-1, IL-6, IL-8, and TNF [16]. LPS is also considered a proatherogenic mediator, as it promotes lipid accumulation in adventitial fibroblasts [17]. Moreover, LPS induces foam cell formation from macrophages by inhibiting the cholesterol efflux. This mechanism is possibly mediated by the adipocyte enhancer-binding protein 1 (AEBP1) as well as alterations in the CD36 receptor and the ATP-binding cassette transporter A1 [18, 19].

Previous descriptive microbiome analyses indicate that members of \(E.\) rysipelasorhiaceae and \(L.\) achnospiraceae families correlated with disease markers (total cholesterol and LDL cholesterol levels) [20]. In relation to metabolic pathways, the genes responsible for peptidoglycan synthesis were enriched in atherosclerosis patients while the phytoene dehydrogenase which is responsible for the lipid-soluble antioxidants metabolism were enriched in healthy individuals [21]. Similarly, in a larger metagenomic study, a higher abundance of \(E.\) enterobacteriaceae and \(S.\) tretococcus spp, in combination with a lower abundance of butyrate-producing bacteria (\(B.\) bacteroides, \(P.\) revotella copri, and \(A.\) listipes shahii) were reported in CVD patients. [22]. Similar data were obtained in the microbiome analysis of patients with carotid atherosclerosis. The enrichment of 21 species was reported, highlighting the presence of \(B.\) eggerthii, \(E.\) cherichia coli and \(K.\) levisella pneumoniae. On the contrary, unclassified \(P.\) revotelloides, \(P.\) revotella copri, \(B.\) bacteroides sp 3_1_19 and \(H.\) emophilus parainfluenzae appeared with greater abundance in healthy individuals. In addition, from 142 identified metabolic pathways, those related to elevated levels of Trimethylamine N-oxide (TMAO) are distinguished [23]. Advances in metagenomics have allowed the identification of various favorable and unfavorable species for health, so the use of the microbiome as a biomarker of cardiometabolic risk has recently been proposed [24]. Furthermore, with the help of artificial intelligence through the discipline of machine learning, a microbiome-based diagnostic test for CVD was developed. This test considers that a core set of the microbiota represents a common denominator for the entire clinical spectrum, and uses 39 taxonomic groups that clearly differentiate subjects with or without CVD [25].

In addition to all the information generated from CVDs patients, the finding that subjects with SCA also develop intestinal dysbiosis is notorious. In these individuals, there is an increased abundance of \(E.\) coli and members of the \(S.\) trectococcus genus. In contrast, member of the \(B.\)acteroides genus and \(F.\) acabiibacterium prausnitzi are more abundant among healthy controls. These findings raise the question about the possibility to develop an early diagnostic test when there are no CVD symptoms yet [26].

2.2. The Microbiota Metabolism Has a Significant Effect in Host Physiology Related to Atherosclerosis

Microbiome studies have shown that bacterial metabolism is perhaps more relevant than description of the taxonomic groups inhabiting the gut, and the changes in metabolic activity obey to environmental factors like the available nutrients [27]. For CVDs, dysbiosis is responsible in part of modifying some of the relevant risk factors, such as obesity [28–32], type II diabetes [33, 34], and inflammation [35]. From all studied metabolites, TMAO has attracted special attention since higher plasma levels were associated with an increased risk of atherosclerosis both in humans and mice [36]. TMAO is
the final product of choline, phosphatidylcholine, L-carnitine, and γ-butyrobetaine metabolism, and the main source is consumption meat, fish, and eggs. The intermediate product trimethylamine (TMA) can also be produced by an endogenous biosynthetic pathway using lysine as substrate to form γ-butyrobetaine [37, 38]. It is still unknown if any other bacterial system has the capability to liberate TMA from diet. The first step in TMAO formation is the generation of TMA by the action of the microbial enzyme complexes (a) CutC/D (the choline utilization TMA lyase

Table 1: Summary of studies analyzing the relationship between microbiota and CVDs.

| Source | Population | Methods | Associated bacterial taxa |
|--------|------------|---------|--------------------------|
| Koren et al. [20] | Case-control study $n = 30$ | 16S rRNA sequencing mouth, stool, and atherosclerotic plaque samples | Erysipelotrichaceae and Lachnospiraceae families correlate with total cholesterol and LDL cholesterol levels which are atherosclerosis markers |
| Karlsson et al. [21] | Case-control study $n = 25$ | Shotgun sequencing. Stool samples | Atherosclerosis: Genus Collinsella Controls: Roseburia and Eubacterium |
| Jie et al. [22] | Case-control study $n = 405$ | Shotgun sequencing. Stool samples | CVD: Higher abundance of Escherichia coli, Klebsiella spp., Enterobacter aerogenes, streptococcus spp., lactobacillus salivarius, Solobacter moorei, and Atopobium parvum, species. Lower abundance of Roseburia intestinalis and Faecalibacterium compare prausnitzi Bacteroides spp., Prevotella copri, and Alistipes shahii |
| Aryal et al. [25] | Case-control study $n = 951$ | Machine learning strategy Fecal 16S ribosomal RNA sequencing | CVD: Bacteroides, Subdoligranulum, clostridium, Megasphaera, Eubacterium, Veillonella, Acidaminococcus, and lusteria. Non-CVD: Faecalibacterium, Ruminococcus, Proteus, Lachnospiara, Brevundimonas, Alistipes, and Neisseria Poor health associated species: Rutherenibacterium lactiformans, Flavonifractor prauisnitzii Bacteroides spp., Prevotella copri, and Alistipes shahii |
| Asnicar et al. [24] | Clinical trial about the responses to dietary composition $n = 1098$ | Shotgun sequencing. Stool samples | CVD: Escherichia, streptococcus, Ruminococcus, lactobacillus, Dorea, Coprococcus, clostridium, Parabacteroides, Eubacterium, and Bifidobacterium Poor health associated species: F. prausnitzii, E. eligens, Oscillibacter sp. 57 20, Romboutsia ilealsis, H. parainfluenzae, Firmicutes bacterium CAG:95, Oscillibacter sp. PC13, V. dispar, Roseburia sp. CAG:182, Veillonella atypica, clostridium sp. CAG:167, V. infantium, B. animalis, P. copri, and Firmicutes bacterium CAG:170 |
| Baragetti et al. [26] | Case-control study $n = 345$ | 16S rRNA and shotgun sequencing. Ultrasound-based analysis for carotid IMT | CAS: Escherichia, streptococcus, Ruminococcus, lactobacillus, Dorea, Coprococcus, clostridium, Parabacteroides, Eubacterium, and Bifidobacterium Poor health associated species: F. prausnitzii, E. eligens, Oscillibacter sp. 57 20, Romboutsia ilealsis, H. parainfluenzae, Firmicutes bacterium CAG:95, Oscillibacter sp. PC13, V. dispar, Roseburia sp. CAG:182, Veillonella atypica, clostridium sp. CAG:167, V. infantium, B. animalis, P. copri, and Firmicutes bacterium CAG:170 |
| Chen et al. [23] | Case-control study $n = 82$ | Shotgun sequencing. Stool samples and ultrasound imaging | CVD: cardiovascular disease; SCA: subclinical atherosclerosis; CAS: carotid atherosclerosis.
system), (b) the CntA/B, or (c) the YeaW/X (carnitine Rieske-type oxygenase/reductase system) [38–41]. These systems are present in the Firmicutes, Proteobacteria, Actinobacteria, and Fusobacteria phyla but absent in the Bacteroidetes group. Some of the bacterial genera reported with these systems include Desulfovibrio, Clostridium, Streptococcus, Klebsiella, Enterobacter, Escherichia, Anaerococcus, Aeromonas, Proteus, Providencia, Vibrio, Collinsella, Desulfoptoculum, Desulfofotae, Desulfofoporus, Desulfotobacterium, Alkaliphilus, Olsenella, Paenibacillus, and Yokenella [42]. The Cuc gene cluster has also been identified in the oral microbiome (supragingival plaque, buccal mucosa, and tongue), which is relevant as periodontal disease and some bacterial species have been associated with atherosclerosis and CVD [43]. Once produced, TMA is absorbed and transported through the blood flow into the liver where it is oxidized by the flavin monoxygenase3 (FMO3) to form TMAO. The FMO3 activity is regulated by bile acids, and their effect on the gene expression is mediated by activation of the nuclear hormone receptor foresaid X FXR (NR1H4) [44]. As flavin-monoxygenases are also present in the marine prokaryotic kingdom, it is thought that TMAO is possibly produced by the intestinal microbiota itself [45].

As higher TMAO levels are described as a potential inductor of endothelial damage and possibly a proatherogenic factor in humans, the role of the genetic components associated with plasma TMAO levels needs to be investigated. In this regard, a comparative Genome-Wide Association Study looked for loci related to plasma TMAO levels, and the results indicated that the genetic component is not that relevant. Instead, it was reported that variations in diet or microbiome are more important than genes in determining the plasma TMAO levels [46].

2.3. Higher TMAO Concentration Correlate with an Increased Risk of Cardiovascular Events. The role of TMAO in CVDs has been remarked by the inhibition of TMAA formation by 3,3-dimethyl-1-butanol (DMB). This action reduces the TMAO levels and in consequence inhibits the macrophage foam cell formation, platelet responsiveness, and thrombus formation [47, 48]. In different studies, TMAO levels correlate positively with an increased risk for the incidence of major adverse cardiovascular events [49, 50], increased mortality in patients with a history of heart failure [51], and with acute coronary syndrome [52]. In a recent meta-analysis from prospective studies including 10,301 individuals with coronary heart disease, higher TMAO levels increased in 58% the risk to suffer a major adverse cardiovascular event. In this study, the authors established a concentration of 5.1 μmol/L as the cut-off value for prognosis [53]. In contrast, some authors argue that plasma levels of TMAO can serve as a predictor for plaque instability rather than an indicator for the extent of atherosclerosis [54].

The mechanism by which TMAO induces atherosclerosis is still poorly understood. One explanation proposes that TMAO promotes macrophage cholesterol uptake by increasing the expression of scavenger receptors such as CD36 and SRA1 [36], as well as the inhibition of the reverse cholesterol transport pathway and alteration of bile acid metabolism [37]. Another proposal is based on the fact that microbiota seem to modulate the platelet hyperresponsiveness and clot formation by TMAO generation and the release of intracellular calcium in platelets [55, 56]. An alternative explanation considers the direct action over endothelial cells and smooth muscle cells, inducing endothelial dysfunction and inflammation. The inflammatory response comprises increased macrophage recruitment and increased expression of adhesion molecules. Among the adhesion molecules with the higher expression are monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 2 (MIP-2), tumor necrosis factor-α (TNF-α), intercellular adhesion molecule 1 (ICAM1), cyclooxygenase 2 (COX2), E-selectin, vascular cell adhesion molecule 1 (VCAM-1), and the CD36 receptor. However, until now no specific TMAO receptor has been identified in endothelial cells [57–59]. Another proposed mechanism implicates the induction of NLRP3 (NOD-like receptor Pyrin domain containing) inflammasome as its activation is critical in foam cell formation and represents the initial step for endothelial dysfunction. This process possibly involves the activation of thioredoxin-interactive protein linked to NLRP3 signaling, via reactive oxygen species (ROS-TXNIP-NLRP3) and the tight-junctions disruption and alteration of endothelial cells permeability leading atherosclerosis [60, 61].

However, the role of higher TMAO levels in atherosclerosis is still controversial, as a diet supplemented with TMAO did not induce atherosclerosis in a mouse model [62]. This suggests that elevated TMAO is just an indicator of dysbiosis rather than a cause for atherosclerosis [63]. Even some authors consider that moderately elevated TMAO is potentially beneficial in cases of pressure-overloaded heart [64]. In agreement with this idea some studies suggest that TMA is responsible for the induction of atherosclerosis, as it exerts a cytotoxic effect on cardiomyocyte [65]; it shows hemodynamic effects in rats [66], and affects the viability of human vascular smooth muscle cells [67]. A more detailed analysis of the mechanisms of action of TMA/ TMAO in atherosclerosis is necessary.

3. Helicobacter pylori Infection and Atherosclerosis

H. pylori is a Gram-negative gastric pathogen that colonizes more than half of the human population inducing chronic active gastritis, peptic ulcer disease, mucosa associated lymphoid tissue lymphoma, and gastric adenocarcinoma. The infection is generally acquired during childhood and may last for decades if not treated. It is characterized by a strong inflammatory process and induction of an active immune response. In response to the infection, cells from the immune system are attracted to the lamina propria by the effect of chemokines like IL-8, monocyte chemotractant protein-1, growth related oncogene-a, and IL-1β. These chemokines are produced and secreted by gastric epithelial cells in response to the action of bacterial virulence factors like the vacuolating cytoxin (VacA), CagA protein, and urease. At the gastric mucosa, the immunocompetent cells are
activated and exert their effector functions such as the production of cytokines (IL-1β, TNF-α, IL-6, IL-12, and IFN-γ), chemokines (IL-8 and MCP-1), nitric oxide (NO), and reactive oxygen species (ROS). If the infection is not resolved, the process is perpetuated evolving into a chronic inflammatory state [68]. The association between *H. pylori* and atherosclerosis is not clearly understood, but it is possible that the chronic inflammatory process induced by the bacterium is an indirect mechanism of endothelial cells damage, favoring the development of atherosclerosis [69, 70].

In 1994, Mendall et al. published the first report about an association between seropositivity to *H. pylori* and coronary heart disease [71]. Since then, multiple studies have investigated this observation, but the underlying mechanisms behind this phenomenon are not known (Table 2). The hypothesis that *H. pylori* has a role in the induction of atherosclerosis is based on the association between anti-*H. pylori* IgG antibodies and adverse cardiovascular disease, arterial stiffness, coronary artery calcium, and subclinical artery stenosis [72–76]. In addition, DNA detection and the successful *H. pylori* isolation from atherosclerotic plaques support the idea of a direct action on the endothelial surface [77–79]. Moreover, this association has also been analyzed in healthy individuals by computed tomography, and the incidence of SCA was higher in *H. pylori* asymptomatic carriers (OR 2.813, 95% confidence interval 1.051 ± 7.528, *P* = 0.04) [80]. But not only the bacterial infection is associated, the presence of antibodies against the CagA virulence factor has also been associated with aortic atherosclerosis and acute coronary events. The CagA protein is the most studied *H. pylori* virulence factor which is encoded by the cag pathogenicity island (cagPAI), and it is present in approximately 60–80% of clinical isolates [81, 82]. One possible explanation for this association is the cross-reaction between the anti-CagA antibodies with epitopes located in the arterial wall [83–86]. On the other hand, it has also been described the presence of extracellular vesicles (exosomes) containing CagA in the serum of *H. pylori* infected patients, and even gastric epithelial cells expressing CagA in *vitro* show the secretion of active CagA-containing exosomes [87]. In animal models infected with *H. pylori*, CagA-containing exosomes derived from gastric epithelial cells promote macrophage-derived foam cell formation and downregulate the expression of cholesterol efflux transporters [88]. In agreement with these reports, Xia et al. showed that an exosome-mediated mechanism induces endothelial dysfunction in a mouse model and in patients infected with cagA-positive strains [89]. More recently, it was found that CagA inhibits the LDL uptake into cells by interacting with the low-density lipoprotein receptor (LDLR) via its C-ter region. Ninomiya et al. hypothesized that this could represent an alternative mechanism by which cagA+ strains lead to hypercholesterolemia that is recognized as a classical risk factor for induction of atherosclerosis [90].

Another explanation for the *H. pylori*-atherosclerosis association considers the induction of endothelial dysfunction by elevated levels of homocysteine. It is known that *H. pylori* gastritis decrease the absorption of vitamin B12 and folic acid and increase the levels of homocysteine and C-reactive protein, which possibly mean the initial step of atherosclerotic plaque formation [91, 92].

Finally, in a recent meta-analysis about the infection prevalence in patients with adverse cardiovascular events that included 40 studies published between January 1, 1990 and January 31, 2020 (*n* = 19,691), it was concluded that *H. pylori* infection increases the risk of developing atherosclerosis and CVD by 51% [93].

### 4. *Helicobacter pylori* Infection and Intestinal Microbiota

Colonization of the gastric mucosa by *H. pylori* not only alters the local ecosystem, but it also may alter the microbial composition at the lower intestinal tract, and in consequence, modulate the concentration of microbial metabolites that can be used as disease markers. Different studies have analyzed the relationship between *H. pylori* and the gut microbiota (Table 3). Some data supporting this idea came from the metabolome of peptic ulcer disease patients due to *H. pylori*. In this analysis, the long-chain fatty acids blood profile appears to be disease-specific, and the authors argue that this remarkable change in the metabolic profile cannot be explained by the presence of a single pathogen in the stomach but by substantial changes in the microbial community at the lower gastrointestinal tract [94]. In infected gerbils, the microbiota analysis shows important changes in the distribution and bacterial density in both the stomach and the duodenum, and in the C57Bl/6 murine model, similar alterations were observed in either the gastric mucosa and the distal gut [95, 96]. In a similar way, *H. pylori* infection seems to modulate the microbial communities in humans. In infected children (6–12 years old), there were significant microbiota changes in comparison to noninfected controls, suggesting that microbial alterations could even be induced at early stages of life [97, 98]. Among the bacterial groups with significant changes in diversity and abundance due to *H. pylori* infection are the phylum *Bacteroidetes*, *Firmicutes*, and *Proteobacteria*. Particularly, there is a notorious decrease in the relative abundance of *Bacteroidetes*, while the *Firmicutes* are increased [99, 100]. At the genera level, the *Lactobacillus* group seems to experiment important changes in their relative abundance. While *Lactobacillus salivarous* experiments, an increased abundance in infected patients, *Lactobacillus acidophilus* is more abundant in noninfected subjects [101]. There is even data suggesting that *H. pylori* influences the composition of fungal populations in the intestinal tract [102]. Apart from the microbiota changes, *H. pylori* is associated with alteration in the microbial metabolism. In a Chinese population study, a reduction in the vitamin B12 biosynthetic module and decreased plasma vitamin B12 concentration was observed in *H. pylori* positive patients [103]. These data agree with previous studies about lower plasma vitamin B12 levels in *H. pylori* patients, but they also offer a potential explanation to the fact that vitamin B12 deficiency relates to SCA and correlates with the categories of coronary artery disease [104–106].
Table 2: Summary of studies analyzing the relationship between H. pylori and CVDs.

| Reference | Samples | Methods | Findings |
|-----------|---------|---------|----------|
| Mendall et al. [71] | Case-control study n = 185 111 coronary heart disease cases and 74 controls | Serology | Coronary heart disease is associated with H. pylori seropositivity. OR 2.15 (1.07 to 4.29 95% CI) P = 0.03 |
| Franceschi et al. [83] | Umbilical cord and atherosclerotic artery sections | Anti-CagA immunohistochemistry | Anti-CagA antibodies cross-react with arterial wall antigens |
| Kowalski et al. [77] | 46 coronary artery disease cases 19 coronary artery postmortem biopsies | PCR (16S rRNA gene) serology (anti-H. pylori and anti-CagA) | Identification of H. pylori DNA in atherosclerotic plaques |
| Shmuely et al. [84] | Prospective study of patients examined for presence of aortic atheroma n = 188 | Transesophageal echocardiography serology (H. pylori western blot (CagA) | The H. pylori infection, with CagA+ strains, was associated with an increase in the incidence of atherosclerosis |
| Gunji et al. [72] | Case-sectional survey n = 5095 | Serology anthropometric and metabolic data | H. Pylori infection was significantly associated with metabolic syndrome. |
| Franceschi et al. [85] | Clinico-pathological study (n = 134), and meta-analysis (9 studies) | Anti-CagA serology and immunohistochemistry | CagA seropositivity was significantly associated with the occurrence of acute coronary events. OR 1.34 (95% CI, 1.15–1.58, P = 0.0003). |
| Kędzia et al. [78] | Atherosclerotic plaques from the femoral and iliac arteries (n = 51) | H. Pylori culture | Positive culture in 3/51 samples |
| Huang et al. [86] | Coronary heart disease patients infected or not infected with H. pylori n = 159 | Anti-CagA serology and metabolic data | Coronary atherosclerosis is more severe in patients with H. pylori cag+ infection (P < 0.05) |
| Park et al. [73] | Case-control study n = 2029 1214 H. p. positive 815 H. p. negative | Serology, Coronary artery calcification score by computed tomography | H. Pylori seropositivity is associated to coronary artery calcification score in SCA |
| Longo-Mbenza et al. [74] | Prospective study (10 years) n = 205 | Carotid ultrasound (IMT) and H. Pylori serology | H. Pylori seropositivity was a predictor for the development of atherosclerotic plaque after adjustment for traditional risk factors. OR 2.3 (95% CI, 1.2-7.2) |
| Mitra et al. [79] | Deep sequencing and metagenomic analysis in atherosclerotic plaques n = 22 | Illumina’s TruSeq next-generation sequencing and fluorescence in situ hybridization | The most prevalent Species in symptomatic atherosclerotic plaques were lactobacillus rhamnosus, Neisseria polysaccharea, helicobacter pylori, and Acidovorax spp. |
| Liu et al. [167] | Meta-analysis 26 studies involving 21,829 individuals | A literature search and selection of studies comparing the prevalence of H. pylori in patients with MI | H. Pylori infection is associated with an increased risk of myocardial infarction. OR 1.73 (95% CI, 1.37–2.17, P < .00001) |
| Raut et al. [92] | Cross sectional study of chronic gastritis patients with or without H. pylori infection n = 80 | Chemiluminescence immunoassay for homocysteine and CRP | Elevated homocysteine levels in H. pylori gastritis induce endothelial dysfunction and may be the basis of the association between H. pylori and coronary artery disease. |
| Shimoda et al. [87] | Analysis of serum samples from gastric cancer patients and healthy controls | LC-MS/MS and TEM | CagA is present in serum exosomes from patients infected with CagA-positive strains. These vesicles may be responsible to deliver CagA and play a role in the development of extra gastric disorders |
| Kim et al. [75] | Cross-sectional study including healthy subjects n = 37,263 | H. Pylori serology. Anthropometric and metabolic data | H. Pylori infection was a significant and independent risk factor for dyslipidemia Higher LDL-C (RR 1.21; 95% CI, 1.12–1.30; P < 0.001) Lower HDL-C (RR 1.10; 95% CI, 1.01–1.18; P = 0.021) |
| Lee et al. [80] | Cross sectional study of healthy subjects n = 463 | Endoscopy, CLO test computed tomography | Coronary artery calcium scores were significantly higher in H. Pylori infected individuals. H. Pylori infection is associated with the |
Table 2: Continued.

| Reference | Samples | Methods | Findings |
|-----------|---------|---------|----------|
| Choi et al. [76] | Cross-sectional study of healthy subjects n = 2,251 | Serology and cardio-ankle vascular index | Hp-seropositivity was significantly associated with arterial stiffness (OR 2.813, 95% CI, 1.051 ± 7.528, P = 0.04) |
| Wang et al. [93] | Meta-analysis 40 case-control and cohort studies n = 19,691 | Studies that analyze the prevalence of H. pylori in patients with adverse cardiovascular events | H. pylori infection increases the risk of developing atherosclerosis and CVD (OR 1.51, 95% CI 1.34–1.70) |
| Xia et al. [89] | Case-control study in humans and in a mouse model | Ultrasound assessment in patients and vascular contraction and relaxation in mice | Endothelial dysfunction observed in H. pylori infection is induced by an exosome-mediated mechanism. |
| Ninomiya et al. [90] | Drosophila model expressing CagA in the adult eye | A large-scale genetic screen using 16S rRNA gene sequencing | Identification of low-density lipoprotein receptor (LDLR) as a novel CagA target for the inhibition of LDL uptake into cells |

Table 3: Summary of studies analyzing the relationship between H. pylori and gut microbiota.

| Reference | Samples | Methods | Findings |
|-----------|---------|---------|----------|
| Ktsoyan et al. [94] | Blood samples 37 FMF patients 14 PU patients 43 healthy controls | Gas chromatography/mass spectrometry | The profile of LCFAs in the human metabolome is disease specific and can potentially be used as a disease marker |
| Yin et al. [95] | Gerbil model infected with H. pylori | Stomach and duodenum bacteria culture | H. Pylori infection changes the distribution and abundance of microflora in the stomach and duodenum |
| Kienesberger et al. [96] | Murin model C57BL/6 | 16S rRNA gene sequencing | H. Pylori infection influences the host microbiota not only in the stomach but also remotely in the intestine |
| Schulz et al. [97] | Cross-sectional study 8 H. pylori positive 16 H. pylori negative | Duodenal biopsies and aspirates 16S rRNA gene sequencing | H. Pylori infection induces changes in the duodenal microbiota Increase in the abundance of proteobacteria |
| Benavides-Ward et al. [98] | Cross-sectional study n = 56 children 28 H. pylori positive 28 H. pylori negative | H. Pylori and 13 genera identified by PCR on feces | There are differences in the microbiota between children with and without H. pylori. The presence of Proteobacteria, Clostridium, Firmicutes, and Prevotella was significantly higher in children with Helicobacter |
| Iino et al. [101] | Cross-sectional study n = 884 | H. Pylori diagnosis by serology and NGS of 16S rRNA gene | H. Pylori infection would be associated with lactobacillus in the human gut microbiota |
| Frost et al. [99] | 212 H. pylori infected and 212 H. pylori Negative subjects | 16S rRNA gene sequencing | H. Pylori infection induce profound alterations and increase the diversity in human fecal microbiota |
| Wang et al. [103] | Cross-sectional study n = 313 128 H. pylori positive 185 H. pylori negative | Shotgun metagenomic sequencing of fecal samples | H. Pylori is associated with changes in human intestinal microbiome, particularly with vitamin B12 biosynthesis |
| Dash et al. [102] | Cross-sectional study n = 60 12 H. pylori positive 48 H. pylori negative | V4 region of 16S rRNA gene sequencing | H. Pylori infection increased the abundance of members of Succinivibrio, Coriobacteriaceae, Enterococcaceae, and Rikenellaceae, as well as Candida glabrata and other unclassified fungi |
| White et al. [107] | Case-control study n = 35 19 H. pylori patients 16 control subjects | 16S rRNA gene sequencing | Increased abundance in H. pylori subjects: Atopobium, Gemellaceae, Micrococcaceae, Gemellales and Rothia |
| Overstreet et al. [135] | C57BL/6 mouse model WT vs GKN1−/− | 16S rRNA gene sequencing | Gkn1−/− mice exhibited a reduced prevalence of bacteria associated to obesity (Firmicutes) |

FMF: familial Mediterranean fever; PU: peptic ulceration; LCFAs: long chain fatty acids.
Another evidence about the altered microbial metabolism due to the infection is the different patterns of fecal fatty acids between *H. pylori* infected and noninfected individuals and the altered bacterial diversity. However, in infected patients some specific taxa are enriched (*Atopobium, Gemella* spp., *Micrococcus* spp, and *Rothia*). It is interesting to note that those enriched taxa belong to the phylum *Firmicutes* and *Actinobacteria*, which are reported to possess the metabolic capability to produce TMA [107].

Very few information about a possible interaction between *H. pylori* and the microbial metabolite TMAO is available. Experimental infection of gastric epithelial cells and exposed to TMAO showed a synergistic effect on the expression levels of immunoinflammatory response genes such as IL-6, CXCL1, CXCL2, FOS, and C3. It is not known if this interaction actually takes place *in vivo*, but if so, it would be important to consider the effects of both conditions to determine their role whether in gastritis or in atherosclerosis development [108]. In a mouse model, choline supplementation of infected mice increased the serum TMAO levels and elevated the concentration of inflammatory components (C reactive protein, LPS, IL-6, TNF-a, and CXCL1). These components may exacerbate the *H. pylori* induced inflammation and modify the richness and diversity of the microbiota, particularly the relative abundance of the Escherichia-Shigella group [109].

4.1. The Inflammation Induced by *H. pylori* Raises a Healing Response That May Have an Effect on the Microbiota. The immune response to *H. pylori* infection is characterized by infiltration of neutrophils and specific immune cells and the release of reactive oxygen species (ROS), such as superoxide anion (\(\text{O}_2^-\)), peroxide hydrogen (\(\text{H}_2\text{O}_2\)), and the hydroxyl radical (\(\text{OH}^-\)). To compensate the oxidative stress, different mechanisms are activated in order to protect the integrity of the mucosa which includes the release of antioxidant enzymes like catalase, superoxide dismutase and glutathione as well as other endogenous antioxidant compounds such as ghrelin and L-carnitine [110].

L-carnitine (L-3-hydroxy-4-N, N, N-trimethylaminobutyrate) is a biomolecule involved in the transport of long chain fatty acids from the cytoplasm to the mitochondrial matrix where \(\beta\)-oxidation takes place. It is also an antioxidant that protects the gastric mucosa by inhibition of the xanthine-oxidase enzyme [111, 112], capture of free radicals [113–116], reduction of neutrophil accumulation [117], protection from peroxide damage [118–120], and inhibition of gastric mucosa damage from ethanol [121]. In mammals, its main source is the food proteins degradation, but it can be synthesized endogenously in the liver and the kidneys from the aminoacids lysine and methionine [122]. However, synthesis de novo has also been reported to take place in the gut of a mouse model [123]. As L-carnitine is also a precursor for TMA, it is not known if these biosynthetic routes are relevant for the TMA cycle that contributes for atherosclerosis development. In particular, *H. pylori* infection, which in many cases lasts for decades, represents a constant stimulus for the synthesis of L-carnitine in the gastrointestinal tract [49, 124].

A second compound involved in the gastric anti-inflammatory response is Gastrokine-1 (GKN1). It is a protein expressed in the superficial/foveolar gastric epithelium (cardia, body, and antrum). GKN1 confers protection and promotes the healing of mucosal lesions by favoring the proliferation and restitution of epithelial cells, and it seems to play a role in suppression of the carcinogenic process [125, 126]. GKN1 is made up of 185 amino acids including an N-terminal signal peptide, and it has a characteristic central domain called the BRICHOS domain, which might be involved in disulfide bridges [127–129]. In *H. pylori* infection, GKN1 expression is downregulated depending on disease severity, so it was thought that GKN1 was completely abolished in gastric cancer cases [130]. However, the expression is not completely suppressed as it is still detected in patients without cancer or even in cancer patients but in nontumoral tissues. These findings possibly represent a tissue repair process and at the same time a tumor containment mechanism [131–133]. Epidemiological studies indicate that between 1-3% of infected people develop cancer, so the lasting effect of GKN1 expression on the rest of the cancer-free population is unknown.

It is thought that the downregulation mechanism involves the activation of the ERK pathway by the CagA virulence factor, promoting the upregulation of the AU-rich element RNA-binding factor 1 (AUF1), that negatively regulates the GKN1 expression [132]. If CagA downregulates GKN1, then the infection with CagA negative strains is a relevant aspect, as it is estimated that between 20-40% of the clinical isolates are cagA negative. On the other hand, some authors propose that GKN1 possibly suppresses the CagA-induced effects on epithelial cells avoiding the gastric cancer progression [134].

In a recent study using a GKN1\(^{-/-}\) mouse model, it was reported that GKN1 indirectly mediates obesity through its effects on the gut microbiota. GKN1 was detected not just in the stomach but also in the small bowel and in the colon. GKN1\(^{-/-}\) mice exhibited an altered gut microbiota with significant reduced prevalence of *Firmicutes*, which was translated in resistance to diet induced obesity in comparison to wild type mice [135]. These findings are consistent with previous reports in which an increased abundance of *Firmicutes* is associated with obesity in both humans and mice [29, 30, 136]. The fact that GKN1 modifies the microbiota to modulate obesity is relevant as obesity is a well-recognized risk factor for CVDs. Moreover, members of the phylum *Firmicutes* have the metabolic ability to produce TMA/TMAO which are strongly associated with atherosclerosis. The precise mechanism by which GKN1 affects the microbiota is not known, but one possibility is the action of its antiamyloidogenic properties to avoid polypeptides aggregation and prevents biofilm formation [137–139]. In the gastrointestinal tract, biofilm formation is a process related to gut homeostasis and disease, and if GKN1 prevents biofilm formation, then the homeostasis and the microbiota equilibrium will be altered [140, 141]. Another possible mechanism is the participation of the BRICHOS domain that seems to be involved in the biosynthesis of antimicrobial peptides [142, 143]. The role of GKN1 in the induction of dysbiosis needs to be further investigated.
4.2. *H. pylori* Might Predispose the Onset of Atherosclerosis through Indirect Modification of the Microbiota. In this review, the data supporting three different associations are presented: *H. pylori*-atherosclerosis, *H. pylori*-microbiota, and microbiota-atherosclerosis, but the connections between these associations and the mechanisms behind them are not clearly understood. Regarding the *H. pylori*-atherosclerosis association, some possible explanations consider, (a) the bacterial direct action over the arterial walls, (b) indirect induction of endothelial damage by the gastric inflammatory process, (c) cross-reaction between antibodies against the CagA antigen with epitopes on the arterial walls, (d) induction of hypercholesterolemia by inhibition of LDL capture, and (e) foam cell formation by regulation of the reverse cholesterol transport. However, none of these explanations are completely satisfactory. Time is a key factor for the natural history of disease in *H. pylori* infection, and the same circumstance occurs in atherosclerosis and CVDs. In both pathologies, the symptoms appear after a long and silent process that can last even for decades. During the asymptomatic periods, there is a balance between damage and the host response, but in atherosclerosis it is possible to identify early signs or SCA [144, 145]. SCA has been documented in *H. pylori* infected adults without a CVD diagnosis [146–148] and in *H. pylori* infected asymptomatic children [149]. In those children, alternations in the microbiota were documented with a strong association with *Prevotella copri*. The association with *P. copri* is interesting because this bacterium has been associated with obesity, insulin resistance, and type 2 diabetes mellitus, which are risk factors for atherosclerosis [150–153]. However, there are contradictory associations between *P. copri* with health and disease. In a recent publication it was found that *P. copri* shows a diet induced strain-level diversity. This diversity is translated into different metabolic capacities, and these findings highlight the relevance of knowing the microbial metabolism rather than just describing the bacterial communities [23, 24, 154].

Here, we propose an alternative hypothesis to explain the association between *H. pylori* and atherosclerosis that involves the induction of gut dysbiosis. Our hypothesis is based on the following findings: (1) the *H. pylori* effect over the microbiota composition, (2) the GKN1 and possibly L-carnitine secretion as part of the anti-inflammatory response against the mucosal damage by *H. pylori*, (3) the presence of GKN1 in the gastric mucosa of *H. pylori* infected patients and in the gut of animal models, (4) the induced dysbiosis by GKN1, particularly in the Firmicutes phyla, and (5) the role of the microbiota in the route of TMA/TMAO production, and the TMAO effects on platelets and endothelial cells (Figure 1).

5. Potential Research Topics to Explore

The get support for the hypothesis proposed in this review, it is necessary to look for answers of several questions that cannot be addressed in a single project. The following ideas are proposed for the search of answers.

The first controversy that needs to be resolved is whether *H. pylori* infection is, in fact, an additional predisposing factor for atherosclerosis. Different studies recognize the infection as a risk factor after adjusting for other confounding variables. However, as far as we know the *H. pylori* prevalence is different throughout the world, and there is a host genetic component that influences the outcome of the host-parasite relationship. These facts make it necessary to establish an analysis for each region and particular population as it has been suggested for microbiota analyses, in which the virulence of the infecting strains should be considered [155]. In our experience, *H. pylori* infection in Mexico is strongly associated with the presence of SCA and coronary artery disease when compared with a non-CVD control group. However, we still do not know if the presence of the cag pathogenicity island is a relevant factor for this association [156].

Once an association is established, it is also necessary to analyze whether there are significant differences in the microbiota between individuals with and without *H. pylori*. Given the nature of the disease, three groups should be compared: patients with CVD, healthy individuals but with evidence of SCA, and a *H. pylori* negative group from the open population and without SCA. If there are significant differences in the microbiota between infected and noninfected groups, then it should be investigated whether there are differences in the metabolic capacities for the synthesis of TMA and TMAO plasma levels.

In a second stage, the analysis in a younger population would be mandatory. Most studies have been performed in adult populations, and we know very little about this problem at an early stage. If we assume that an atheroma grows during a long period of time, it becomes relevant to identify changes in the microbiota, coronary artery calcium, TMAO, and GKN1 levels in young adults, teenagers, and children. A longitudinal study would be ideal, but the time and resources to perform this kind of analysis make it very complicated and practically impossible. As an alternative, a transversal study with individuals classified into different age groups could be more feasible.

In a final stage, if there are sufficient evidences that *H. pylori* contributes to atherosclerosis, then it should be evaluated whether its eradication or the microbiota modification represent an alternative preventive therapy. Eradication is a complex decision that will require a cost-benefit analysis. In this regard, the Japanese authorities implemented an early eradication program in 2013, with a consequent reduction in gastric cancer cases [157, 158]. It would be interesting to analyze whether this massive eradication has any effect on the frequency of CVDs. At the end, identifying people at higher risk and taking preventive measures is the main objective of the health authorities worldwide.

In relation to microbiome, the use of microbial metabolites shows encouraging results in animal models. On the one hand, the use of cyclic D, L-α-peptides shows reduction of plasma total cholesterol and atherosclerotic plaques, and on the other, the use of 2,3,5,4′-Tetrahydroxy-stilbene-2-O-β-D-glucoside (TSG) modifies the overall microbiota and inhibits the atheroma formation [159, 160]. In a similar
way, the use of probiotics to inhibit TMA/TMAO concentrations is under study. Some groups of archaea can use methyl compounds (including TMA) as a substrate to produce methane [161]. In particular, the species *Methanobrevibacter smithii* has shown to decrease the plasma TMAO levels, but all these research areas need further investigation [162].

Another area that needs to be investigated is the role of TMA in bacterial communication. Recently, it was reported that *Streptomyces venezuelae*, a Gram-positive bacterium belonging to the phylum *Actinobacteria* develops a type of growth called "exploratory". This form of growth consists of an unbranched aerial hypha that can exceed abiotic surfaces in response to unfavorable environmental conditions such as low glucose concentrations or increased pH. This aerial hypha is also induced to other streptomyces species by chemical communication based on volatile organic compounds (VOC). Theses VOC are potential long-term messengers that allow communication between fungi and bacteria over long distances [163]. In the genus *Streptomyces*, the identified VOC is TMA. TMA has also a negative effect on the bacterial growth by reduction of iron availability and alteration of antibiotic resistance [164–166]. So, taking into consideration that the phylum *Actinobacteria*, and the genus *Streptomyces* are part of the the human microbiota, then it is possible to think that TMA may have a role in gut dysbiosis when the environmental conditions are adverse.

### 6. Conclusion

*H. pylori* infection and the microbial metabolite TMAO have been associated with atherosclerosis and CVD. Both infection and elevated TMAO levels are potential factors that may increase the risk for atherosclerosis. However, the mechanisms behind the *H. pylori* induced damage to endothelial tissues are not well understood. In this review, we presented the information regarding the role of microbiota in atherosclerosis as well as the induction of dysbiosis by *H. pylori* infection. Finally, we proposed a hypothesis to explain how *H. pylori* may indirectly induce atherosclerosis by modification of the microbiota. The possibly role of GKN1 in this process, favoring the growth of bacterial groups with the metabolic capability to produce TMA from Choline and L-carnitine. (g) The increased production of TMA may also alter the gut microbiota composition by reducing the iron availability, affecting the growth of other bacterial communities. (b) The increased TMA concentration favors the activity of FMO3 in the liver, resulting in an increased serum levels of TMAO, which is an inducer of endothelial damage. (i) The long-lasting insult into the endothelial cells may result in the development of SCA.
erosclerosis, but the exact mechanism behind this associa-
tion to indirectly induce the development of atherosclerosis. It is known that
H. pylori infection and gut dysbiosis are associated with ath-
erosclerosis, but the exact mechanism behind this association is not completely understood. Recent publications indicate that H. pylori gastric colonization can also alter the intestinal microbiota, and in this review, we present the information that support the hypothesis about the effect that H. pylori infection exert over the gut microbiota composi-
tion to indirectly induce the development of atherosclerosis.

Conflicts of Interest
Francisco Avilés-Jiménez has no conflict of interest.

References
[1] World Health Organization, “Cardiovascular diseases,” 2021, http://www.who.int/cardiovascular_diseases/es/.
[2] The Diabetes Control and Complications Trial (DCCT)/Epi-
demiology of Diabetes Interventions and Complications (EDIC) Study Research Group, “Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up,” Diabetes Care, vol. 39, pp. 686–693, 2016.
[3] R. R. Holman, D. R. Matthews, and H. A. Neil, “Follow-up of intensive glucose control in type 2 diabetes [1],” New England Journal of Medicine, vol. 360, no. 4, pp. 416–418, 2009.
[4] M. S. Ellulu, I. Patimah, H. Khaza’ai, A. Rahmat, and Y. Abed, “Obesity & inflammation: the linking mechanism & the compi-
lcations,” Archives of Medical Science, vol. 13, no. 4, pp. 851–863, 2017.
[5] T. B. Olesen, M. Pareek, J. V. Stidsen et al., “Association between antecedent blood pressure, hypertension-mediated organ damage and cardiovascular outcome,” Blood Pressure, vol. 29, pp. 1–9, 2020.
[6] H. Kiriyama, H. Kaneko, H. Itoh, Y. Yoshida, K. Nakanishi, and Y. Mizuno, “Effect of cigarette smoking on carotid artery atherosclerosis: a community - based cohort study,” Heart and Vessels, vol. 35, no. 1, 2020.
[7] N. Ding, Y. Sang, J. Chen et al., “Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic dis-
bases,” Journal of the American College of Cardiology, vol. 74, no. 4, pp. 498–507, 2019.
[8] S. Ripatti, E. Tikkanen, M. Orho-Melander et al., “Articles a mulitlocus genetic risk score for coronary heart disease E: case-control and prospective cohort analyses,” The Lancet, vol. 376, no. 9750, pp. 1393–1400, 2010.
[9] R. Ross, “Atherosclerosis an inflammatory disease,” The New England Journal of Medicine, vol. 340, pp. 115–126, 1999.
[10] The Human Microbiome Jumpstart Reference Strains Con-
sortium, K. E. Nelson, G. M. Weinstock et al., “A catalog of reference genomes,” Science, vol. 328, no. 994, p. 2010, 2010.
[11] L. K. Ursell, J. L. Metcalf, L. W. Parfrey, and R. Knight, “Defining the human microbiome,” Nutrition Reviews, vol. 70, 2012.
[12] S. A. Whiteside, H. Razvi, S. Dave, G. Reid, and P. Jeremy, “The microbiome of the urinary tract — a role beyond infec-
tion,” Nature Publishing Group, vol. 12, no. 2, pp. 81–90, 2015.
[13] G. Berg, D. Rybakova, D. Fischer et al., “Microbiome definition revisited: old concepts and new challenges,” Micro-
bio, vol. 8, no. 1, pp. 1–22, 2020.
[14] P. B. Eckburg, E. M. Bik, C. N. Bernstein et al., “Diversity of the human intestinal microbial Flora,” Science, vol. 308, no. 5728, pp. 1635–1638, 2005.
[15] B. Stecher, L. Maier, and W. D. Hardt, “‘Blooming’ in the gut: how dysbiosis might contribute to pathogen evolution,” Nature Reviews. Microbiology, vol. 11, no. 4, pp. 277–284, 2013.
[16] H. Li and B. Sun, “Toll-like receptor 4 in atherosclerosis,” Journal of Cellular and Molecular Medicine, vol. 11, no. 1, pp. 88–95, 2007.
[17] J. Wang, Y. Si, C. Wu et al., “Lipopolysaccharide promotes lipid accumulation in human adventitial fibroblasts via TLR4-NF-κ B pathway,” Lipids in Health and Disease, vol. 11, pp. 1–9, 2012.
[18] A. Majdalawieh and H. Ro, “The international journal of bio-
chemistry LPS-induced supression of macrophage cholesterol efflux is mediated by adipocyte enhancer-binding protein 1,” The International Journal of Biochemistry & Cell Biology, vol. 41, pp. 1518–1525, 2009.
[19] X. Li, C. Wang, X. Xiang, F. Chen, C. Yang, and J. Wu, “Por-
phyromonas gingivalis lipopolysaccharide increases lipid accumulation by affecting CD36 and ATP-binding cassette transporter A1 in macrophages,” Oncology Reports, vol. 30, pp. 1329–1336, 2013.
[20] O. Koren, A. Spor, J. Felin et al., “Human oral, gut, and pla-
que microbiota in patients with atherosclerosis,” Proceedings of the National Academy of Sciences, vol. 108, Supplement_1, pp. 4592–4598, 2011.
[21] F. H. Karlsson, F. Fåk, I. Nookaew et al., “Symptomatic ath-
erosclerosis is associated with an altered gut metagenome,” Nature Communications, vol. 3, p. 1245, 2012.
[22] Z. Jie, H. Xia, S. L. Zhong et al., “The gut microbiome in atherosclerotic cardiovascular disease,” Nature Communica-
tions, vol. 8, no. 845, pp. 1–11, 2017.
[23] J. Chen, Q. Qin, S. Yan et al., “Gut microbiome alterations in patients with carotid atherosclerosis,” Frontiers in Cardiovas-
cular Medicine, vol. 8, pp. 1–12, 2021.
[24] F. Ansicnar, S. E. Berry, A. M. Valdes et al., “Microbiome con-
nections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals,” Nature Medicine, vol. 27, no. 2, pp. 321–332, 2021.
[25] S. Aryal, A. Alimadadi, I. Manandhar, B. Joe, and X. Cheng, “Machine learning strategy for gut microbiome-based diag-
nostic screening of cardiovascular disease,” Hypertension, vol. 76, pp. 1555–1562, 2020.
[26] A. Baragetti, M. Severgnini, E. Olmastroni et al., “Gut micro-
bioa functional dysbiosis relates to individual diet in subclin-
ic carotid atherosclerosis,” Nutrients, vol. 13, pp. 1–18, 2021.
[27] B. A. Kappel, L. De Angelis, M. Heiser et al., “Cross-omics analysis revealed gut microbiome-related metabolic
pathways underlying atherosclerosis development after anti-biotics treatment,” *Molecular Metabolism*, vol. 36, no. March, article 100976, 2020.

[28] F. Bäckhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 44, pp. 15718–15723, 2004.

[29] R. E. Ley, F. Bäckhed, P. Turnbaugh, C. A. Lozupone, R. D. Knight, and J. I. Gordon, “Obesity alters gut microbial ecology,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, pp. 11070–11075, 2005.

[30] P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, “An obesity-associated gut microbiome with increased capacity for energy harvest,” *Nature*, vol. 444, no. 7122, pp. 1027–1131, 2006.

[31] F. Bäckhed, J. K. Manchester, C. F. Semenkovich, and J. I. Gordon, “Mechanisms underlying the resistance to diet-induced obesity in germ-free mice,” *Proceedings of the National Academy of Sciences*, vol. 104, no. 3, pp. 979–984, 2007.

[32] P. J. Turnbaugh, M. Hamady, T. Yatsunenko et al., “A core gut microbiome in obese and lean twins,” *Nature*, vol. 457, no. 7228, pp. 480–484, 2009.

[33] N. Larsen, F. K. Vogensen, F. W. Van Den Berg et al., “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” *PLOS One*, vol. 5, no. 2, 2010.

[34] J. Qin, Y. Li, Z. Cai et al., “A metagenome-wide association study of gut microbiota in type 2 diabetes,” *Nature*, vol. 490, no. 7418, pp. 55–60, 2012.

[35] D. N. Frank, A. L. S. Amand, R. A. Feldman, E. C. Boedecker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the national academy of sciences of the United States of America,” *Proceedings Of The National Academy Of Sciences*, vol. 104, no. 34, pp. 13780–13785, 2007.

[36] Z. Wang, E. Klipfell, B. J. Bennett et al., “Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease,” *Nature*, vol. 472, no. 7341, pp. 57–63, 2011.

[37] R. A. Koeth, Z. Wang, B. S. Levison et al., “Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis,” *Nature Medicine*, vol. 19, no. 5, pp. 576–585, 2013.

[38] R. A. Koeth, B. S. Levison, M. K. Culley et al., “γ-Butyrobetaine is a pro-atherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO,” *Cell Metabolism*, vol. 20, no. 5, pp. 799–812, 2014.

[39] C. J. Thibodeaux and W. A. Van Der Donk, “Converging on a mechanism for cholinel degradation,” *Proceedings of the National Academy of Sciences*, vol. 109, no. 52, pp. 21184–21185, 2012.

[40] S. Craciun and E. P. Balskus, “Microbial conversion of choline to trimethylamine requires a glycerol radical enzyme,” *Proceedings of the National Academy of Sciences*, vol. 109, no. 52, pp. 21307–21312, 2012.

[41] Y. Zhu, E. Jameson, M. Crosatti et al., “Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota,” *Proceedings of the National Academy of Sciences*, vol. 111, no. 11, pp. 4268–4273, 2014.

[42] A. Martinez-del Campo, S. Bodea, H. A. Hamer et al., “Characterization and detection of a widely distributed gene cluster that predicts anaerobic choline utilization by human gut bacteria,” *MBio*, vol. 6, no. 2, pp. 1–12, 2015.

[43] B. J. Levin, Y. Y. Huang, S. C. Peck et al., “A prominent glycol radical enzyme in human gut microorganisms metabolizes trans-4-hydroxy-L-proline,” *Science*, vol. 355, no. 6325, 2017.

[44] B. J. Bennett, T. Q. de Aguiar Vallim, Z. Wang et al., “Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation,” *Cell Metabolism*, vol. 17, no. 1, pp. 49–60, 2013.

[45] Y. Chen, N. A. Patel, A. Cribbie, J. H. Scrivens, and J. C. Murrell, “Bacterial flavin-containing monooxygenase is trimethylamine monooxygenase,” *Proceedings of the National Academy of Sciences*, vol. 108, pp. 17791–17796, 2011.

[46] J. Hartiala, B. J. Bennett, W. T. Wang et al., “Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a pro-atherogenic metabolite of choline and L-carnitine,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 34, no. 6, pp. 1307–1313, 2015.

[47] Z. Wang, A. B. Roberts, J. A. Bufla et al., “Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis,” *Cell*, vol. 163, no. 7, pp. 1585–1595, 2015.

[48] A. B. Roberts, X. Gu, J. A. Bufla et al., “Development of a gut microbe-targeted non-lethal therapeutic to inhibit thrombosis potential,” *Nature Medicine*, vol. 24, pp. 1407–1417, 2018.

[49] W. W. Tang, Z. Wang, B. S. Levison et al., “Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk,” *New England Journal of Medicine*, vol. 368, no. 17, pp. 1575–1584, 2013.

[50] Z. Wang, W. W. Tang, J. A. Bufla et al., “Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide,” *European Heart Journal*, vol. 35, pp. 904–910, 2014.

[51] W. W. Tang, Z. Wang, Y. Fan et al., “Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure,” *Journal of the American College of Cardiology*, vol. 64, no. 18, 2014.

[52] X. S. Li, S. Obeid, R. Klingenberg et al., “Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors,” *European Heart Journal*, vol. 38, pp. 814–824, 2017.

[53] M. E. Yao, P. Da Liao, X. J. Zhao, and L. Wang, “Trimethylamine-N-oxide has prognostic value in coronary heart disease: a meta-analysis and dose-response analysis,” *BMC Cardiovascular Disorders*, vol. 20, no. 1, pp. 1–9, 2020.

[54] Y. C. Koay, Y. C. Chen, J. A. Wali et al., “Plasma levels of trimethylamine-N-oxide can be increased with ‘healthy’ and ‘unhealthy’ diets and do not correlate with the extent of atherosclerosis but with plaque instability,” *Cardiovascular Research*, vol. 117, pp. 435–449, 2020.

[55] W. Zhu, J. C. Gregory, E. Org et al., “Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk,” *Cell*, vol. 165, no. 1, pp. 111–124, 2016.

[56] S. M. Skye, W. Zhu, K. A. Romano et al., “Microbial transplantation with human gut commensals containing CufC is sufficient to transmit enhanced platelet reactivity and thrombosis potential,” *Circulation Research*, vol. 123, no. 10, pp. 1164–1176, 2018.

[57] M. M. Seldin, Y. Meng, H. Qi et al., “Trimethylamine N-oxide promotes vascular inflammation through signaling of
mitogen-activated protein kinase and nuclear factor-KB,” *Journal of the American Heart Association*, vol. 5, article e002767, pp. 1–12, 2016.

[58] G. Ma, B. Pan, Y. Chen et al., “Trimethylamine N-oxide in atherosclerosis: impairing endothelial self-repair capacity and enhancing monocyte adhesion,” *Bioscience Reports*, vol. 37, pp. 1–12, 2017.

[59] J. Geng, C. Yang, B. Wang et al., “Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway,” *Biomedicine & Pharmacotherapy*, vol. 97, pp. 941–947, 2018.

[60] X. Sun, X. Jiao, Y. Ma et al., “Biochemical and biophysical research communications trimethylamine N-oxide induces in fl ammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 in fl ammasome,” *Biochemical and Biophysical Research Communications*, vol. 1, pp. 1–8, 2016.

[61] K. M. Boini, T. Hussain, P. L. Li, and S. S. Koka, “Trimethylamine-N-oxide instigates NLRP3 infl ammasome activation and endothelial dysfunction,” *Cellular Physiology and Biochemistry*, vol. 77204, pp. 152–162, 2017.

[62] P. Aldana-herández, K. Leonard, Y. Zhao, J. M. Curtis, C. J. Field, and R. L. Jacobs, “Dietary choline or trimethylamine N-oxide supplementation does not influence atherosclerosis development in Ldlr −/− Apoe −/− male mice,” *The Journal of Nutrition*, vol. 10, pp. 1–7, 2019.

[63] B. Landfald, J. Valeur, A. Berstad, and J. Raa, “Microbial trimethylamine-N-oxide as a disease marker: something fishy?,” *Microbial Ecology in Health and Disease*, vol. 28, no. 1, pp. 4–6, 2017.

[64] T. Huc, A. Drapala, M. Gawryś et al., “Chronic, low-dose TMAO treatment reduces diastolic dysfunction and heart fibrosis in hypertensive rats,” *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 315, pp. H1805–H1820, 2018.

[65] K. Jaworska, D. Herling, G. Mosieniak et al., “TMA, a forgotten uremic toxin, but not TMAO, is involved in cardiovascular pathology,” *Toxins (Basel)*, vol. 11, no. 9, pp. 1–11, 2019.

[66] K. Jaworska, K. Bielinska, M. Gawryś-Kopczynska, and M. Ufnal, “TMA (trimethylamine), but not its oxide TMAO (trimethylamine-N-oxide), exerts haemodynamic effects: implications for interpretation of cardiovascular actions of gut microbiome,” *Cardiovascular Research*, vol. 115, no. 14, pp. 1948-1949, 2019.

[67] K. Jaworska, M. Konop, T. Hutsh et al., “Trimethylamine but not trimethylamine oxide increases with age in rat plasma and affects smooth muscle cells viability,” *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, vol. 75, no. 7, pp. 1276–1283, 2020.

[68] K. Robinson and J. C. Atherton, “The spectrum of helicobacter-mediated diseases,” *Annual Review of Pathology*, vol. 16, pp. 123–144, 2021.

[69] M. Chmielea, A. Gajewski, and K. Rudnicka, “Helicobacter pylori vs coronary heart disease - searching for connections,” *World Journal of Cardiology*, vol. 7, no. 4, p. 187, 2015.

[70] A. Krupa, W. Gonciarz, P. Rusek-Wala et al., “Heliocobacter pylori infection acts synergistically with a high-fat diet in the development of a proinflammatory and potentially proatherogenic endothelial cell environment in an experimental model,” *International Journal of Molecular Sciences*, vol. 22, no. 7, 2021.

[71] M. A. Mendall, P. M. Goggins, N. Molineaux et al., “Relation of helicobacter pylori infection and coronary heart disease,” *Heart*, vol. 71, pp. 437–439, 1994.

[72] T. Gunji, N. Matsuhashi, H. Sato et al., “Heliocobacter pylori infection is significantly associated with metabolic syndrome in the Japanese population,” *Official Journal of the American College of Gastroenterology* | ACG, vol. 103, pp. 3005–3010, 2008.

[73] M. J. Park, S. H. Choi, D. Kim et al., “Association between helicobacter pylori seropositivity and the coronary artery calcium score in a screening population,” *Gut and Liver*, vol. 5, no. 3, pp. 321–327, 2011.

[74] B. Longo- menza, J. N. Nsenga, E. Mokondjimbo, J. R. Ibara, and B. Ellenga-mbolla, “Helicobacter pylori infection is identified as a cardiovascular risk factor in central Afri cans,” *Vascular Health and Risk Management*, vol. 8, pp. 455–461, 2012.

[75] T. J. Kim, H. Lee, M. Kang et al., “Helicobacter pylori is associated with dyslipidemia but not with other risk factors of cardiovascular disease,” *Scientific Reports*, vol. 6, no. July, pp. 1–8, 2016.

[76] J. M. Choi, S. H. Lim, Y. M. Han et al., “Association between helicobacter pylori infection and arterial stiffness: results from a large cross-sectional study,” *PLoS One*, vol. 14, article e0221643, 2019.

[77] M. Kowalski, W. Rees, P. C. Konturek et al., “Detection of helicobacter pylori specific DNA in human atheromatous coronary arteries and its association to prior myocardial infarction and unstable angina,” *Digestive and Liver Disease*, vol. 34, no. 6, pp. 398–402, 2002.

[78] A. Kędzia, M. Ciecierski, M. Wierzbowska, A. Kufel, and E. Kwapisz, “Isolation of helicobacter pylori from femoral or iliac atherosclerotic plaques,” *Acta Angiologica*, vol. 16, no. 3, pp. 129–134, 2010.

[79] S. Mitra, D. I. Drautz-Moses, M. Alhede et al., “In silico analyses of metagenomes from human atherosclerotic plaque samples,” *Microbiome*, vol. 3, no. 1, p. 38, 2015.

[80] M. Lee, H. Baek, J. S. Park et al., “Current helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: across-sectional study,” *PLoS One*, vol. 13, no. 3, pp. 1–13, 2018.

[81] I. Apel, E. Jacobs, M. Kist, and W. Breid, “Antibody response of patients against a 120 kDa surface protein of Campylobacter pylori. Zentralblatt für Bakteriologie. Mikrobiologie und Hygiene,” *Series A: Medical Microbiology, Infectious Diseases, Virology, Parasitology*, vol. 268, no. 2, pp. 271–276, 1988.

[82] T. L. Cover, C. P. Dooley, and M. J. Blaser, “Characterization of and human serologic response to proteins in helicobacter pylori broth culture supernatants with vacuolizing cytotoxin activity,” *Infection and Immunity*, vol. 58, no. 3, pp. 603–610, 1990.

[83] F. Franceschi, A. R. Selvveda, A. Gasbarrini et al., “Cross-reactivity of anti-CagA antibodies with vascular wall antigens,” *Circulation*, vol. 106, pp. 430–435, 2002.

[84] H. Shmuely, D. J. Passaro, M. Vaturi et al., “Association of CagA+ helicobacter pylori infection with aortic atheroma,” *Atherosclerosis*, vol. 179, no. 1, pp. 127–132, 2005.

[85] F. Franceschi, G. Niccoli, G. Ferrante et al., “CagA antigen of helicobacter pylori and coronary instability: insight from a clinico-pathological study and a meta-analysis of 4241 cases,” *Atherosclerosis*, vol. 202, no. 2, pp. 535–542, 2009.
[86] B. Huang, Y. Chen, and Q. Xie, “CagA-positive helicobacter pylori strains enhanced coronary atherosclerosis by increasing serum OxLDL and HsCRP in patients with coronary heart disease,” *Digestive Diseases and Sciences*, vol. 56, pp. 109–114, 2011.

[87] A. Shimoda, K. Ueda, S. Nishiumi, N. Murata-kamiya, and S. Mukai, “Exosomes as nanocarriers for systemic delivery of the helicobacter pylori virulence factor CagA,” *Nature Publishing Group*, vol. 6, pp. 1–9, 2016.

[88] S. Yang, Y. P. Xia, X. Y. Luo et al., “Exosomal CagA derived from helicobacter pylori-infected gastric epithelial cells induces macrophage foam cell formation and promotes atherosclerosis,” *Journal of Molecular and Cellular Cardiology*, vol. 135, pp. 40–51, 2019.

[89] X. Xia, L. Zhang, J. Chi et al., “Helicobacter pylori infection impairs endothelial function through an exosome-mediated mechanism,” *Journal of the American Heart Association*, vol. 9, no. 6, 2020.

[90] R. Ninomiya, S. Kubo, T. Baba et al., “Inhibition of low-density lipoprotein uptake by helicobacter pylori virulence factor CagA,” *Biochemical and Biophysical Research Communications*, vol. 556, pp. 192–198, 2021.

[91] L. Santarelli, M. Gabrielli, F. Cremonini et al., “Atrophic gastritis as a cause of hyperhomocysteinemia,” *Alimentary Pharmacology & Therapeutics*, vol. 19, pp. 107–111, 2004.

[92] S. C. Raut, V. W. Patil, S. M. Dalvi, G. D. Bakhshi, and G. Hospitals, “Helicobacter pylori gastritis, a presequale to coronary plaque,” *Clinics And Practice*, vol. 5, pp. 1–4, 2015.

[93] B. Wang, M. Yu, R. Zhang, S. Chen, Y. Xi, and G. Duan, “A meta-analysis of the association between helicobacter pylori infection and risk of atherosclerotic cardiovascular disease,” *Helicobacter*, vol. 25, 2020.

[94] Z. A. Ktsoyan, N. V. Beloborodova, A. M. Sedrakyan et al., “Profiles of microbial fatty acids in the human metabolome are disease-specific,” *Frontiers in Microbiology*, vol. 1, p. 148, 2011.

[95] Y. N. Yin, C. L. Wang, X. W. Liu et al., “Gastric and duodenal microflora analysis after long-term helicobacter pylori infection in Mongolian gerbils,” *Helicobacter*, vol. 16, no. 5, pp. 389–397, 2011.

[96] S. Kienesberger, L. Cox, A. Livano et al., “Gastric helicobacter pylori infection affects local and distant microbial populations and host responses,” *Cell Reports*, vol. 14, no. 6, pp. 1395–1407, 2016.

[97] C. Schulz, K. Schütte, N. Koch et al., “The active bacterial assemblages of the upper Gi tract in individuals with and without helicobacter infection,” *Gut*, vol. 67, no. 2, pp. 216–225, 2016.

[98] A. Benavides-Ward, F. Vasquez-Achaya, W. Silva-Caso et al., “Helicobacter pylori and its relationship with variations of gut microbiota in asymptomatic children between 6 and 12 years,” *BMC Research Notes*, vol. 11, no. 1, pp. 1–7, 2018.

[99] F. Frost, T. Kacprowski, M. Rühlemann et al., “Helicobacter pylori infection associates with fecal microbiota composition and diversity,” *Scientific Reports*, vol. 9, no. 1, pp. 1–10, 2019.

[100] J. J. Gao, Y. Zhang, M. Gerhard et al., “Association between gut microbiota and helicobacter pylori-related gastric lesions in a high-risk population of gastric cancer,” *Frontiers in Cellular and Infection Microbiology*, vol. 8, pp. 1–12, 2018.

[101] C. Iino, T. Shimoyama, D. Chinda et al., “Infection of helicobacter pylori and atrophic gastritis influence lactobacillus in gut microbiota in a Japanese population,” *Frontiers in Immunology*, vol. 9, pp. 1–7, 2018.

[102] N. R. Dash, G. Khoder, A. M. Nada, M. T. Al, and B. Id, “Exploring the impact of helicobacter pylori on gut microbiome composition,” *PloS One*, vol. 14, pp. 1–13, 2019.

[103] D. Wang, Y. Li, H. Zhong et al., “Alterations in the human gut microbiome associated with helicobacter pylori infection,” *FEBS Open Bio*, vol. 9, no. 9, pp. 1552–1560, 2019.

[104] S. F. Celik and E. Celik, “Subclinical atherosclerosis and impaired cardiac autonomic control in pediatric patients with vitamin B12 deficiency,” *Nigerian Journal of Clinical Practice*, vol. 21, no. 8, pp. 1012–1016, 2018.

[105] G. S. Monasso, J. F. Felix, S. G. Heil, Y. B. de Rijke, R. Gaillard, and V. W. V. Jaddoe, “Vitamin B12, folate and homocysteine concentrations during pregnancy and early signs of atherosclerosis at school-age,” *Clinical Nutrition*, vol. 40, no. 9, pp. 5133–5140, 2021.

[106] Y. Ma, D. Peng, C. Liu, C. Huang, and J. Luo, “Serum high concentrations of homocysteine and low levels of folic acid and vitamin B12 are significantly correlated with the categories of coronary artery diseases,” *BMC Cardiovascular Disorders*, vol. 17, no. 1, pp. 1–7, 2017.

[107] B. White, J. D. Sterrett, Z. Grigoryan et al., “Characterization of gut microbiome and metabolome in helicobacter pylori patients in an underprivileged community in the United States,” *World Journal of Gastroenterology*, vol. 27, no. 33, pp. 5575–5594, 2021.

[108] D. Wu, M. Cao, J. Peng et al., “The effect of trimethylamine N-oxide on helicobacter pylori-induced changes of immunoinflammatory genes expression in gastric epithelial cells,” *International Immunopharmacology*, vol. 43, pp. 172–178, 2017.

[109] S. Li, D. Wu, M. Cao et al., “Effects of choline supplementation on liver biology, gut microbiota, and inflammation in helicobacter pylori-infected mice,” *Life Sciences*, vol. 259, 2020.

[110] A. M. Rizzo, “Endogenous antioxidants and radical scavengers,” in *Bio-Farms for Nutraceuticals*, pp. 52–67, Springer, Boston, Massachusetts, 2010.

[111] C. Di Giacomo, F. Latteri, C. Fichera et al., “Effect of acetyl-L-carnitine on lipid peroxidation and xanthine oxidase activity in rat skeletal muscle,” *Neurochemical Research*, vol. 18, no. 11, pp. 1157–1162, 1993.

[112] M. H. Dong and J. D. Kaunitz, “Gastroduodenal mucosal defense,” *Current Opinion in Gastroenterology*, vol. 24, pp. 599–606, 2006.

[113] P. J. Rani and C. Panneerselvam, “Carnitine as a free radical scavenger in aging,” *Experimental Gerontology*, vol. 36, no. 10, pp. 1713–1726, 2001.

[114] K. A. Naidu, “Vitamin C in human health and disease is still a mystery? An overview,” *Nutrition Journal*, vol. 2, p. 7, 2003.

[115] G. Şener, K. Paskaloglu, H. Şatiroglu, I. Alican, A. Kaçmaz, and A. Sakarcan, “L-carnitine ameliorates oxidative damage due to chronic renal failure in rats,” *Journal of Cardiovascular Pharmacology*, vol. 43, no. 5, pp. 698–705, 2004.

[116] I. Gülcin, “Antioxidant and antiradical activities of L-carnitine,” *Life Sciences*, vol. 78, no. 8, pp. 803–811, 2006.

[117] N. Derin, A. Agac, Z. Bayram, M. Asar, and V. N. Içgut-Uysal, “Effects of L-carnitine on neutrophil-mediated ischemia-reperfusion injury in rat stomach,” *Cell Biochemistry and Function*, vol. 24, no. 5, pp. 437–442, 2006.
[118] J. H. Yoon, H. S. Seo, S. S. Choi et al., “Gastrokine 1 inhibits the carcinogenic potentials of helicobacter pylori CagA,” Carcinogenesis, vol. 35, no. 11, pp. 2619–2629, 2014.

[119] A. M. Overstreet, B. E. Grayson, A. Boger et al., “Gastrokine 1, an anti-amyloidogenic protein secreted by the stomach, regulates diet-induced obesity,” Scientific Reports, vol. 11, pp. 1–13, 2021.

[120] J. Alarcón, S. I. Lorenzo-Nazario, H. Jiménez-Wences et al., “Women with chronic follicular gastritis positive for Helicobacter pylori infection and subclinical atherosclerosis,” Medicine, vol. 100, article e27840, 2021.

[121] X. Wang, Q. He, D. Jin, K. Yao, and X. Zou, “Association between Helicobacter pylori infection and subclinical atherosclerosis,” Medicine, vol. 100, article e27840, 2021.

[122] X. Wang, Q. He, D. Jin, K. Yao, and X. Zou, “Association between Helicobacter pylori infection and subclinical atherosclerosis,” Medicine, vol. 100, article e27840, 2021.

[123] X. Wang, Q. He, D. Jin, K. Yao, and X. Zou, “Association between Helicobacter pylori infection and subclinical atherosclerosis,” Medicine, vol. 100, article e27840, 2021.

[124] X. Wang, Q. He, D. Jin, K. Yao, and X. Zou, “Association between Helicobacter pylori infection and subclinical atherosclerosis,” Medicine, vol. 100, article e27840, 2021.
[150] J. U. Scher, A. Szcesnak, R. S. Longman et al., “Expansion of intestinal prevotella copri correlates with enhanced susceptibility to arthritis,” *eLife*, vol. 2, pp. 1–20, 2013.

[151] H. K. Pedersen, V. Gudmundsdottir, H. B. Nielsen et al., “Human gut microbes impact host serum metabolome and insulin sensitivity,” *Nature*, vol. 535, no. 7612, pp. 376–381, 2016.

[152] M. Duan, Y. Wang, Q. Zhang, R. Zou, M. Guo, and H. Zheng, “Characteristics of gut microbiota in people with obesity,” *PLoS One*, vol. 16, no. 8, pp. 1–15, 2021.

[153] D. D. Wang, L. H. Nguyen, Y. Li et al., “The gut microbiome modulates the protective association between a Mediterranean diet and cardiometabolic disease risk,” *Nature Medicine*, vol. 27, no. 2, pp. 333–343, 2021.

[154] F. De Filippis, E. Pasolli, A. Tett et al., “Distinct genetic and functional traits of human intestinal Prevotella copri strains are associated with different habitual diets,” *Cell Host & Microbe*, vol. 25, no. 3, pp. 444–453, 2019.

[155] N. Fei, B. P. Bernabé, L. Lie et al., “The human microbiota is associated with cardiometabolic risk across the epidemiologic transition,” *PLoS One*, vol. 14, no. 7, pp. 1–24, 2019.

[156] G. Vargas-Alarcón, F. Avilés-Jiménez, F. Mejia-Sánchez, N. Pérez-Hernádez, G. Cardoso-Saldaña, and R. Posadas-Sánchez, “Helicobacter pylori infection and DNMT3a polymorphism are associated with the presence of premature coronary artery disease and subclinical atherosclerosis. Data from the GEA Mexican study,” *Microbial Pathogenesis*, vol. 170, 2022.

[157] M. Tsuda, M. Asaka, M. Kato et al., “Effect on helicobacter pylori eradication therapy against gastric cancer in Japan,” *Helicobacter*, vol. 22, no. 5, pp. 1–6, 2017.

[158] A. Kowada and M. Asaka, “Economic and health impacts of introducing helicobacter pylori eradication strategy into national gastric cancer policy in Japan: a cost-effectiveness analysis,” *Helicobacter*, vol. 26, no. 5, pp. 1–10, 2021.

[159] P. B. Chen, A. S. Black, A. L. Sobel et al., “Directed remodeling of the mouse gut microbiome inhibits the development of atherosclerosis,” *Nature Biotechnology*, vol. 38, no. 11, pp. 1–10, 2020.

[160] F. Li, T. Zhang, Y. He et al., “Inflammation inhibition and gut microbiota regulation by TSG to combat atherosclerosis in Apoe−/− mice,” *Journal of Ethnopharmacology*, vol. 247, article 112232, 2020.

[161] J. F. Brugère, G. Borrel, N. Gaci, W. Tottey, P. W. O’toole, and C. Malpuech-Brugère, “Archaeabacteria: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease,” *Gut Microbes*, vol. 5, pp. 5–10, 2014.

[162] A. Ramezani, T. D. Nolin, I. R. Barrows et al., “Gut colonization with methanogenic archaea lowers plasma trimethylamine N-oxide concentrations in apolipoprotein e−/− mice,” *Scientific Reports*, vol. 8, no. 1, pp. 1–11, 2018.

[163] R. Schmidt, D. W. Etalo, V. De Jager et al., “Microbial small talk: volatiles in fungal-bacterial interactions,” *Frontiers in Microbiology*, vol. 6, pp. 1–12, 2016.

[164] S. Létoffé, B. Audrain, and S. P. Bernier, “Aerial exposure to the bacterial volatile compound trimethylamine modifies antibiotic resistance of physically separated bacteria by raising culture medium pH,” *MBio*, vol. 5, no. 1, pp. 1–12, 2014.

[165] S. E. Jones, L. Ho, C. A. Rees, J. E. Hill, J. R. Nodwell, and M. A. Elliott, “Streptomycyes exploration is triggered by fungal interactions and volatile signals,” *eLife*, vol. 6, pp. 1–21, 2017.

[166] S. E. Jones, C. A. Pham, M. P. Zambri, J. McKillip, E. E. Carlson, and A. Elliott, “Streptomycyes volatile compounds influence exploration and microbial community dynamics by altering iron availability,” *MBio*, vol. 10, no. 2, pp. 1–18, 2019.

[167] J. Liu, F. Wang, and S. Shi, “Helicobacter pylori Infection Increase the Risk of Myocardial Infarction : A Meta-Analysis of 26 Studies Involving more than 20, 000 Participants,” *Helicobacter*, vol. 20, pp. 176–183, 2015.